06:37 AM EST, 02/23/2026 (MT Newswires) -- Gilead Sciences ( GILD ) said on Monday that it will acquire Arcellx ( ACLX ) for $7.8 billion, expanding its CAR T-cell therapy offerings.

Under the agreement, Gilead said it will pay $115 per share in cash, a 68% premium over Arcellx's ( ACLX ) 30-day average share price, plus a contingent value right of $5 per share.

The company said the US Food and Drug Administration has accepted the marketing application for Arcellx's ( ACLX ) lead CAR T-cell therapy, Anito-cel, for multiple myeloma patients, with a decision expected by Dec. 23.

The drugmaker said the deal, expected to close in Q2, would boost earnings per share starting in 2028, following FDA approval of Anito-cel.

Gilead currently owns roughly 11.5% of Arcellx ( ACLX ), the company added.